Entries by connective

Abcam most cited antibody supplier for IHC in 2023

Cambridge, UK — March 25, 2024 — Abcam, a global life science company working together with researchers to advance science and enable faster breakthroughs, today announces it has been named ‘Supplier Succeeding in IHC’, and was highly commended in a further three categories in CiteAb’s prestigious annual industry awards. CiteAb’s ‘Supplier Succeeding in IHC’ award […]

Abcam appoints Markus Lusser as new President

MARCH 18, 2024 – Abcam today announced the appointment of Markus Lusser as President. A seasoned Danaher executive, Markus joins Abcam at a pivotal moment as the company transitions into the Danaher Life Sciences portfolio. His extensive commercial and digital experience across the life sciences and medical device industries will help build on Abcam’s momentum […]

Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales

Cambridge, UK / Waltham, MA, December 4, 2023 – Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE: DHR) (‘Danaher’) for $24.00 per share in […]

Abcam Acquisition by Danaher has Received all Identified Clearances; Transaction Expected to Close on December 6, 2023

Cambridge, UK / Waltham, MA, November 17, 2023 – Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE: DHR) (‘Danaher’) for $24.00 per share […]

Shareholders of Abcam Approve Proposed Acquisition by Danaher

Cambridge, UK / Waltham, MA, November 6, 2023 – Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE: DHR) (‘Danaher’), today announced that its […]

Leading Independent Proxy Advisor Glass Lewis Joins ISS in Recommending Shareholders Vote “FOR” Danaher Corporation’s Proposed Acquisition of Abcam 

Both Leading Proxy Advisors ISS and Glass Lewis Acknowledge the Thorough Process Undertaken by the Abcam Board in Reaching an Agreement that Provides a Compelling Premium and Certainty of Value to Abcam Shareholders Cambridge, U.K. / Waltham, MA, October 23, 2023 – Abcam plc (Nasdaq: ABCM) (‘Abcam,’ the ‘Group’ or the ‘Company’), a global leader […]

Independent Directors of Abcam highlight compelling reasons for shareholders to support proposed sale to Danaher

Cambridge, U.K. / Waltham, MA, October 12, 2023 – Abcam plc (Nasdaq: ABCM) (‘Abcam,’ the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today filed an investor presentation with the U.S. Securities and Exchange Commission (available online at https://corporate.abcam.com/investors/danaher-abcam), underscoring why the proposed sale of Abcam to Danaher […]

Abcam files and mails Scheme Circular seeking approval of acquisition of Abcam by Danaher for $24.00 per share 

Cambridge, U.K. / Waltham, MA, October 5, 2023 – Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today filed and mailed a scheme circular (the ‘Scheme Circular‘) in connection with the acquisition of Abcam by Danaher Corporation (NYSE: DHR) (‘Danaher’), announced on […]

Abcam plc Statement on Dr. Jonathan Milner’s Announcement

CAMBRIDGE, England & WALTHAM, Mass. – Abcam plc (Nasdaq: ABCM) (“Abcam” or the “Company”), notes today’s announcement by Dr. Jonathan Milner. The Company considers it surprising that Dr. Milner has taken active steps to oppose the deal without reviewing the full details in the Scheme Circular to be published in connection with the proposed acquisition […]